Innate Pharma S.A. (IPHA)

NASDAQ: IPHA · IEX Real-Time Price · USD
2.025
-0.105 (-4.93%)
At close: Jun 24, 2024, 3:59 PM
2.020
-0.005 (-0.25%)
After-hours: Jun 24, 2024, 5:33 PM EDT
-4.93%
Market Cap 163.52M
Revenue (ttm) 68.49M
Net Income (ttm) -8.41M
Shares Out 80.95M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 30,410
Open 2.090
Previous Close 2.130
Day's Range 2.020 - 2.110
52-Week Range 1.810 - 3.290
Beta 0.71
Analysts Strong Buy
Price Target 11.50 (+467.9%)
Earnings Date Mar 21, 2024

About IPHA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head an... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 17, 2019
Employees 179
Stock Exchange NASDAQ
Ticker Symbol IPHA
Full Company Profile

Financial Performance

In 2023, Innate Pharma's revenue was 61.64 million, an increase of 6.88% compared to the previous year's 57.67 million. Losses were -7.57 million, -86.97% less than in 2022.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to one analyst, the rating for IPHA stock is "Strong Buy" and the 12-month stock price forecast is $11.5.

Price Target
$11.5
(467.90% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that updated efficacy and safety results ...

7 days ago - Business Wire

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced favorable results from the Phase 2 TELLOMAK stu...

20 days ago - Business Wire

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming investor conferences.

27 days ago - Business Wire

Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that five abstracts with Innate's drug ca...

4 weeks ago - Business Wire

Outcome of Innate Pharma's 2024 Annual General Meeting

MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2024 Annual General Meeting.

4 weeks ago - Business Wire

Innate Pharma: Clarification Regarding SAR443579 Designation

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that in an abstract published on 14 May 2...

4 weeks ago - Business Wire

Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drug ca...

5 weeks ago - Business Wire

Innate Pharma Reports First Quarter 2024 Business Update and Financial Results

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the...

5 weeks ago - Business Wire

Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for Q1 business update.

6 weeks ago - Business Wire

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024.

2 months ago - Business Wire

Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in the P...

2 months ago - Business Wire

Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that first preclinical data for i...

2 months ago - Business Wire

Innate Pharma Announces Its Participation in Upcoming Investor Conference

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming Investor Conference.

2 months ago - Business Wire

Innate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma files its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F.

2 months ago - Business Wire

Innate Pharma Reports Full Year 2023 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma reports Full Year 2023 financial results and business update.

3 months ago - Business Wire

Innate Pharma Announces Its Participation to Upcoming Investor Conference

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are sc...

3 months ago - Business Wire

Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference ...

3 months ago - Business Wire

Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma

MARSEILLE, France--(BUSINESS WIRE)--First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma.

3 months ago - Business Wire

Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to present Nectin-4 Antibody Drug Conjugate IPH45 preclinical data at AACR 2024.

3 months ago - Business Wire

Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Admin...

6 months ago - Business Wire

Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has strengthened the Company's le...

6 months ago - Business Wire

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to lice...

Other symbols: SNY
6 months ago - Business Wire

Innate Pharma Announces Leadership Change

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Mondher Mahjoubi has resigned from his position as Chief Execu...

6 months ago - Business Wire

Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that the updated efficacy and safety results from an open-...

7 months ago - Business Wire

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced positive final results from the Phase 2 TELLOMAK s...

7 months ago - Business Wire